Article Menu
- Academic Editor
- Subscribe SciFeed
- Recommended Articles
- Related Info Links
-
More by Authors Links
- on DOAJ
- Janssen, J.
- Löwenberg, B.
- Manz, M.
- Bargetzi, M.
- Biemond, B.
- von dem Borne, P.
- Breems, D.
- Brouwer, R.
- Chalandon, Y.
- Deeren, D.
- Efthymiou, A.
- Gjertsen, B.
- Graux, C.
- Gregor, M.
- Heim, D.
- Hess, U.
- Hoogendoorn, M.
- Jaspers, A.
- Jie, A.
- Jongen-Lavrencic, M.
- Klein, S.
- Klift, M. van der
- Kuball, J.
- Lammeren-Venema, D. van
- Legdeur, M.
- Loosdrecht, A. van de
- Maertens, J.
- Kooy, M. van Marwijk
- Moors, I.
- Nijziel, M.
- Obbergh, F. van
- Oosterveld, M.
- Pabst, T.
- Poel, M. van der
- Sinnige, H.
- Spertini, O.
- Terpstra, W.
- Tick, L.
- Velden, W. van der
- Vekemans, M.
- Vellenga, E.
- Weerdt, O. de
- Westerweel, P.
- Stüssi, G.
- Norden, Y. van
- Ossenkoppele, G.
- on Google Scholar
- Janssen, J.
- Löwenberg, B.
- Manz, M.
- Bargetzi, M.
- Biemond, B.
- von dem Borne, P.
- Breems, D.
- Brouwer, R.
- Chalandon, Y.
- Deeren, D.
- Efthymiou, A.
- Gjertsen, B.
- Graux, C.
- Gregor, M.
- Heim, D.
- Hess, U.
- Hoogendoorn, M.
- Jaspers, A.
- Jie, A.
- Jongen-Lavrencic, M.
- Klein, S.
- Klift, M. van der
- Kuball, J.
- Lammeren-Venema, D. van
- Legdeur, M.
- Loosdrecht, A. van de
- Maertens, J.
- Kooy, M. van Marwijk
- Moors, I.
- Nijziel, M.
- Obbergh, F. van
- Oosterveld, M.
- Pabst, T.
- Poel, M. van der
- Sinnige, H.
- Spertini, O.
- Terpstra, W.
- Tick, L.
- Velden, W. van der
- Vekemans, M.
- Vellenga, E.
- Weerdt, O. de
- Westerweel, P.
- Stüssi, G.
- Norden, Y. van
- Ossenkoppele, G.
- on PubMed
- Janssen, J.
- Löwenberg, B.
- Manz, M.
- Bargetzi, M.
- Biemond, B.
- von dem Borne, P.
- Breems, D.
- Brouwer, R.
- Chalandon, Y.
- Deeren, D.
- Efthymiou, A.
- Gjertsen, B.
- Graux, C.
- Gregor, M.
- Heim, D.
- Hess, U.
- Hoogendoorn, M.
- Jaspers, A.
- Jie, A.
- Jongen-Lavrencic, M.
- Klein, S.
- Klift, M. van der
- Kuball, J.
- Lammeren-Venema, D. van
- Legdeur, M.
- Loosdrecht, A. van de
- Maertens, J.
- Kooy, M. van Marwijk
- Moors, I.
- Nijziel, M.
- Obbergh, F. van
- Oosterveld, M.
- Pabst, T.
- Poel, M. van der
- Sinnige, H.
- Spertini, O.
- Terpstra, W.
- Tick, L.
- Velden, W. van der
- Vekemans, M.
- Vellenga, E.
- Weerdt, O. de
- Westerweel, P.
- Stüssi, G.
- Norden, Y. van
- Ossenkoppele, G.
Need Help?
Order Article Reprints
Journal: Cancers, 2021
Volume: 13
Number: 672
672
Article:
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Authors:
by
Jeroen Janssen, Bob Löwenberg, Markus Manz, Mario Bargetzi, Bart Biemond, Peter von dem Borne, Dimitri Breems, Rolf Brouwer, Yves Chalandon, Dries Deeren, Anna Efthymiou, Bjørn-Tore Gjertsen, Carlos Graux, Michael Gregor, Dominik Heim, Urs Hess, Mels Hoogendoorn, Aurelie Jaspers, Asiong Jie, Mojca Jongen-Lavrencic, Saskia Klein, Marjolein van der Klift, Jürgen Kuball, Danielle van Lammeren-Venema, Marie-Cecile Legdeur, Arjan van de Loosdrecht, Johan Maertens, Marinus van Marwijk Kooy, Ine Moors, Marten Nijziel, Florence van Obbergh, Margriet Oosterveld, Thomas Pabst, Marjolein van der Poel, Harm Sinnige, Olivier Spertini, Wim Terpstra, Lidwine Tick, Walter van der Velden, Marie-Christiane Vekemans, Edo Vellenga, Okke de Weerdt, Peter Westerweel, Georg Stüssi, Yvette van Norden and Gert Ossenkoppeleadd
Show full author list
remove
Hide full author list
Link:
https://www.mdpi.com/2072-6694/13/4/672
MDPI offers high quality article reprints with convenient shipping to destinations worldwide. Each reprint features a 270 gsm bright white cover
and 105 gsm premium white paper, bound with two stitches for durability and printed in full color. The cover design is customized to your article
and designed to be complimentary to the journal.
Cite
Janssen, J.; Löwenberg, B.; Manz, M.; Bargetzi, M.; Biemond, B.; von dem Borne, P.; Breems, D.; Brouwer, R.; Chalandon, Y.; Deeren, D.; et al. Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers 2021, 13, 672. https://doi.org/10.3390/cancers13040672
Janssen J, Löwenberg B, Manz M, Bargetzi M, Biemond B, von dem Borne P, Breems D, Brouwer R, Chalandon Y, Deeren D, et al. Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers. 2021; 13(4):672. https://doi.org/10.3390/cancers13040672
Chicago/Turabian StyleJanssen, Jeroen, Bob Löwenberg, Markus Manz, Mario Bargetzi, Bart Biemond, Peter von dem Borne, Dimitri Breems, Rolf Brouwer, Yves Chalandon, Dries Deeren, and et al. 2021. "Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS" Cancers 13, no. 4: 672. https://doi.org/10.3390/cancers13040672
APA StyleJanssen, J., Löwenberg, B., Manz, M., Bargetzi, M., Biemond, B., von dem Borne, P., Breems, D., Brouwer, R., Chalandon, Y., Deeren, D., Efthymiou, A., Gjertsen, B.-T., Graux, C., Gregor, M., Heim, D., Hess, U., Hoogendoorn, M., Jaspers, A., Jie, A., ... Ossenkoppele, G. (2021). Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers, 13(4), 672. https://doi.org/10.3390/cancers13040672
